{
    "nct_id": "NCT04939792",
    "title": "Optimization of Blood Levels of 25(OH)-Vitamin D in African Americans",
    "status": "COMPLETED",
    "last_update_time": "2023-06-06",
    "description_brief": "Two-thirds of the US population, particularly African Americans (AA), is at risk for inadequate or deficient 25-hydroxy-vitamin D (25(OH)VD). Epidemiological studies demonstrate an association between better health outcomes and higher blood levels of 25(OH)VD . Randomized controlled clinical trials have shown that, while supraphysiological high doses of VD are needed to achieve adequate blood levels of 25(OH)VD, not all subjects respond to them. Recent studies have also questioned the therapeutic effects of high-dose VD supplementation. Severe VD deficiency has been associated independently with the future risk of mild cognitive impairment (MCI) and dementia. A reduction in GSH and an increase in the oxidative stress levels of serum, erythrocytes, and circulating lymphocytes has been observed in MCI and Alzheimer disease, findings similar to those in VD deficient persons. Scholarly reviews conclude that excess oxidative stress is one of the major risk factors for AD and support a potential therapeutic role for L-cysteine (LC, a GSH precursor) and vitamin D (VD) supplementation in the treatment of Alzheimer disease symptoms. This application presents the investigators' design for a randomized, double-blind, placebo-controlled clinical trial to test the hypothesis that supplementation with VD in combination with L-cysteine (LC) is more successful at optimizing the statuses of 25(OH)VD \\[biological signatures\\] and simultaneously decreasing TNF-\u03b1, IR \\[functional or clinical outcomes\\], and oxidative stress, suggesting a better therapeutic approach compared with supplementation with VD alone in AA subjects.",
    "description_detailed": "N/A",
    "phase": [
        "EARLY_PHASE1"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": null,
    "target_category": "disease-targeted small molecule",
    "drug": [
        "Vitamin D (cholecalciferol / 25-hydroxy-vitamin D)",
        "L-cysteine (LC) \u2014 glutathione precursor; often studied clinically via N-acetylcysteine (NAC) formulations"
    ],
    "placebo": [
        "matched placebo"
    ],
    "explanation_target": [
        "Reason: The trial tests oral supplementation with vitamin D and L-cysteine to optimize 25(OH)D levels and to raise glutathione/reduce oxidative stress and inflammatory markers (TNF-\u03b1, insulin resistance) because oxidative stress and low 25(OH)D are epidemiologically linked to MCI/Alzheimer\u2019s risk. Vitamin D deficiency has been associated with higher dementia/Alzheimer risk in cohort and meta-analytic studies. \ue200cite\ue202turn0search2\ue202turn0search0\ue201",
        "Act: Extracted interventions \u2014 Vitamin D (25[OH]D optimization) and L-cysteine (a cysteine/GSH precursor). Vitamin D supplementation dose-response in African Americans and the difficulty of achieving target 25(OH)D levels are documented in randomized trials, supporting the trial rationale. L-cysteine (and clinically NAC) act as glutathione precursors and have been studied for antioxidant/neuroprotective effects in preclinical and some clinical work. \ue200cite\ue202turn0search1\ue202turn1search4\ue202turn1search1\ue201",
        "Mapping to categories: Both interventions are small-molecule nutritional/medicinal compounds (vitamin and amino acid/thiol). The study aims to modify biological signatures and oxidative/inflammatory pathways implicated in AD (a disease-modifying approach) rather than delivering a biologic (e.g., monoclonal antibody) or solely treating cognition or neuropsychiatric symptoms. Therefore the best fit among the provided categories is 'disease-targeted small molecule'.",
        "Reflect: Confirmation and ambiguity \u2014 The trial is not a biologic (no antibody/vaccine) and not primarily a symptomatic cognitive-enhancer or neuropsychiatric-targeted drug. Although the interventions are dietary/supplemental and not classical anti-amyloid/tau agents, they target disease-relevant biology (oxidative stress, inflammation, vitamin D deficiency) and so fit the provided 'disease-targeted small molecule' definition. If the user prefers a stricter interpretation that reserves 'disease-targeted' only for drugs directly targeting amyloid/tau, one could instead label this 'N/A' or 'cognitive enhancer' depending on primary outcomes; but given the stated intention to change disease-related biomarkers and mechanisms, 'disease-targeted small molecule' is the most accurate choice. \ue200cite\ue202turn0search2\ue202turn1search4\ue201"
    ],
    "agent_type": "R) Multi-target",
    "explanation_agent": [
        "Reason: The trial tests oral vitamin D (cholecalciferol / 25\u2011OH\u2011D optimization) and L\u2011cysteine (a cysteine/glutathione precursor) to raise 25(OH)D and glutathione/reduce oxidative stress and inflammatory markers \u2014 i.e., interventions intended to modify both oxidative stress and inflammation pathways that are implicated in AD risk. \ue200cite\ue202turn0search1\ue202turn1search0\ue202turn2search5\ue201",
        "Act: Extracted interventions and mechanisms: vitamin D supplementation aims to correct 25(OH)D deficiency (epidemiologically linked to higher dementia/AD risk and with putative neuroprotective/anti\u2011inflammatory effects); L\u2011cysteine (and clinically used NAC formulations) supplies cysteine to support glutathione biosynthesis and direct thiol antioxidant activity. These map to CADRO categories for Oxidative Stress (G) and Inflammation (F). Representative sources: vitamin D\u2014dose/epidemiology and brain effects; NAC/L\u2011cysteine\u2014mechanism as GSH precursor and antioxidant, and small clinical AD studies. \ue200cite\ue202turn0search5\ue202turn0search2\ue202turn1search1\ue202turn1search3\ue201",
        "Reflect: Because the study intentionally targets more than one disease\u2011relevant pathway (oxidative stress and inflammation) with small\u2011molecule nutritional/medicinal agents, the most appropriate CADRO classification is R) Multi\u2011target (multiple mechanistic targets). If one forced a single pathway label, the strongest single match would be G) Oxidative Stress (L\u2011cysteine/NAC) with close overlap with F) Inflammation (vitamin D immunomodulatory effects), but the presence of both justifies 'Multi\u2011target.' \ue200cite\ue202turn1search0\ue202turn2search5\ue202turn0search5\ue201",
        "Web search results supporting the mapping (selected key sources cited above):",
        "- Systematic/meta\u2011analytic evidence linking low 25(OH)D to increased dementia/AD risk. \ue200cite\ue202turn0search1\ue202turn0search2\ue201",
        "- Neurology and related reviews describing brain VDR (vitamin D receptor), neuroprotective and anti\u2011inflammatory actions of vitamin D. \ue200cite\ue202turn0search5\ue201",
        "- Reviews and mechanistic papers showing NAC/L\u2011cysteine are cysteine donors that boost glutathione (GSH) and act as antioxidants, with reported effects on oxidative/inflammatory markers and some clinical studies in AD. \ue200cite\ue202turn1search0\ue202turn1search1\ue202turn1search3\ue201",
        "- Reviews summarizing the role of oxidative stress in AD pathogenesis and the rationale for antioxidant/antioxidant\u2011support therapies. \ue200cite\ue202turn2search5\ue202turn2search1\ue201",
        "Overall output: R) Multi-target \u2014 the trial uses small\u2011molecule nutritional/precursor interventions that act on multiple disease\u2011relevant pathways (primarily oxidative stress and inflammation), so 'Multi\u2011target' best fits CADRO."
    ]
}